Ocular manifestations of Wegener's granulomatosis

Expert Review of Ophthalmology

Volumn 2, Issue 1, 2007, Pages 91-103

  Taylor, Simon r J ^a   Salama, Alan D ^b   Pusey, Charles D ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

antineutrophil cytoplasmic antibodies; orbital; scleritis; vasculitis; Wegener

Indexed keywords

EID: 66049131358     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.1.91     Document Type: Article

References (81)

1. Hoffman GS. “Wegener’s granulomatosis”: the path traveled since 1931. Medicine (Baltimore) 73 (6), 325–329 (1994).
2. Kallenberg CG, Rarok A, Stegeman CA, Limburg PC. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. Autoimmun. Rev. 1 (1–2), 61–66 (2002).
3. Afshari NA, Afshari MA, Foster CS. Inflammatory conditions of the eye associated with rheumatic diseases. Curr. Rheumatol. Rep. 3 (5), 453–458 (2001).
4. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116 (6), 488–498 (1992).
5. Design of the Wegener’s Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials 23 (4), 450–468 (2002).
6. Harman LE, Margo CE. Wegener’s granulomatosis. Surv. Ophthalmol. 42 (5), 458–480 (1998).
7. Abdou NI, Kullman GJ, Hoffman GS et al. Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J. Rheumatol. 29 (2), 309–316 (2002).
8. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 43 (5), 1021–1032 (2000).
9. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 43 (2), 414–419 (2000).
10. Harper SL, Letko E, Samson CM et al. Wegener’s granulomatosis: the relationship between ocular and systemic disease. J. Rheumatol. 28 (5), 1025–1032 (2001).
11. Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum. 48 (8), 2299–2309 (2003).
12. Sadiq SA, Jennings CR, Jones NS, Downes RN. Wegener’s granulomatosis: the ocular manifestations revisited. Orbit 19 (4), 253–261 (2000).
13. Thorne JE, Jabs DA. Ocular manifestations of vasculitis. Rheum. Dis. Clin. North Am. 27 (4), 761–779 (2001).
14. Lohrmann C, Uhl M, Kotter E et al. Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature. Eur. J. Radiol. 53 (3), 471–477 (2005).
15. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am. J. Med. 117 (1), 39–50 (2004).
16. Little MA, Pusey CD. Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. Nephrology (Carlton) 10 (4), 368–376 (2005).
17. Rasmussen N. Consensus therapeutic regimens for ANCA-associated systemic vasculitis. The European Community Systemic Vasculitis Study Group. Lancet 349 (9057), 1029–1030 (1997).
18. Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist’s perspective. Curr. Opin. Rheumatol. 13 (1), 3–11 (2001).
19. Stone JH, Francis HW. Immune-mediated inner ear disease. Curr. Opin. Rheumatol. 12 (1), 32–40 (2000).
20. Knight JM, Hayduk MJ, Summerlin DJ, Mirowski GW. “Strawberry” gingival hyperplasia: a pathognomonic mucocutaneous finding in Wegener granulomatosis. Arch. Dermatol. 136 (2), 171–173 (2000).
21. McCluskey P, Powell RJ. The eye in systemic inflammatory diseases. Lancet 364 (9451), 2125–2133 (2004).
22. Takanashi T, Uchida S, Arita M, Okada M, Kashii S. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome: report of two cases and review of the literature. Ophthalmology 108 (6), 1129–1133 (2001).
23. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am. J. Ophthalmol. 130 (4), 469–476 (2000).
24. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology 102 (4), 687–692 (1995).
25. Robinson MR, Lee SS, Sneller MC et al. Tarsal–conjunctival disease associated with Wegener’s granulomatosis. Ophthalmology 110 (9), 1770–1780 (2003).
26. Langford CA, Sneller MC, Hallahan CW et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum. 39 (10), 1754–1760 (1996).
27. Tauber J, Sainz de la Maza M, Hoang-Xuan T, Foster CS. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 9 (1), 66–73 (1990).
28. Woo TL, Francis IC, Wilcsek GA et al. Australasian orbital and adnexal Wegener’s granulomatosis. Ophthalmology 108 (9), 1535–1543 (2001).
29. Perry SR, Rootman J, White VA. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology 104 (4), 683–694 (1997).
30. Aries PM, Both M. Destructive eye lesions in Wegener’s granulomatosis. N. Eng. J. Med. 352 (4), 392 (2005).
31. Talar-Williams C, Sneller MC, Langford CA et al. Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener’s granulomatosis. Br. J. Ophthalmol. 89 (4), 493–497 (2005).
32. Ghanem RC, Chang N, Aoki L, Santo RM, Matayoshi S. Vasculitis of the lacrimal sac wall in Wegener granulomatosis. Ophthal. Plast. Reconstr. Surg. 20 (3), 254–257 (2004).
33. Mandl LA, Solomon DH, Smith EL et al. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch. Intern. Med. 162 (13), 1509–1514 (2002).
34. Stone JH, Talor M, Stebbing J et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res. 13 (6), 424–434 (2000).
35. Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J. Immunol. Methods 196 (1), 1–15 (1996).
36. Reuter M, Biederer J, Both M et al. Radiology of the primary systemic vasculitides. Rofo 175 (9), 1184–1192 (2003).
37. Simmons JT, Leavitt R, Kornblut AD, Fauci AS. CT of the paranasal sinuses and orbits in patients with Wegener’s granulomatosis. Ear Nose Throat J. 66 (4), 134–140 (1987).
38. Francis IC, Kappagoda MB, Cole IE, Bank L, Dunn GD. Computed tomography of the lacrimal drainage system: retrospective study of 107 cases of dacryostenosis. Ophthal. Plast. Reconstr. Surg. 15 (3), 217–226 (1999).
39. Courcoutsakis NA, Langford CA, Sneller MC et al. Orbital involvement in Wegener granulomatosis: MR findings in 12 patients. J. Comput. Assist. Tomogr. 21 (3), 452–458 (1997).
40. Fechner FP, Faquin WC, Pilch BZ. Wegener’s granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope 112 (11), 1945–1950 (2002).
41. Kalina PH, Lie JT, Campbell RJ, Garrity JA. Diagnostic value and limitations of orbital biopsy in Wegener’s granulomatosis. Ophthalmology 99 (1), 120–124 (1992).
42. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch. Ophthalmol. 121 (4), 491–499 (2003).
43. Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case–control study. Arthritis Rheum. 48 (3), 814–823 (2003).
44. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 335 (1), 16–20 (1996).
45. Christen U, von Herrath MG. Infections and autoimmunity – good or bad? J. Immunol. 174 (12), 7481–7486 (2005).
46. Harper L, Cockwell P, Adu D, Savage CO. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. 59 (5), 1729–1738 (2001).
47. Harper L, Ren Y, Savill J, Adu D, Savage CO. Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am. J. Pathol. 157 (1), 211–220 (2000).
48. Radford DJ, Luu NT, Hewins P, Nash GB, Savage CO. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum. 44 (12), 2851–2861 (2001).
49. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110 (7), 955–963 (2002).
50. Pfister H, Ollert M, Frohlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104 (5), 1411–1418 (2004).
51. Little M, Smyth C, Smith J et al. In vivo effects of the induction of ANCA on leukocyte adhesion and transmigration as assessed by intravital microscopy. J. Am. Soc. Nephrol. 15, 693A (2004).
52. Tam FW, Sanders JS, George A et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol. Dial. Transplant. 19 (11), 2761–2768 (2004).
53. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxf.) 39 (6), 585–595 (2000).
54. Langford CA. Treatment of ANCA-associated vasculitis. N. Engl. J. Med. 349 (1), 3–4 (2003).
55. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 114 (6), 463–469 (2003).
56. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin. Proc. 72 (8), 737–747 (1997).
57. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16 (10), 2018–2027 (2001).
58. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J. Rheumatol. 26 (5), 1134–1139 (1999).
59. Waiser J, Budde K, Braasch E, Neumayer HH. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am. J. Kidney Dis. 34 (3), e9 (1999).
60. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum. 47 (3), 326–332 (2002).
61. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349 (1), 36–44 (2003).
62. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosis. Arthritis Rheum. 51 (2), 278–283 (2004).
63. Etanercept plus standard therapy for Wegener’s granulomatosis. N. Engl. J. Med. 352 (4), 351–361 (2005).
64. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48 (8), 2122–2127 (2003).
65. Booth A, Harper L, Hammad T et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15 (3), 717–721 (2004).
66. Stone JH, Holbrook JT, Marriott MA et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum. 54 (5), 1608–1618 (2006).
67. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44 (12), 2836–2840 (2001).
68. Lockwood CM, Thiru S, Stewart S et al. Treatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies. QJM 89 (12), 903–912 (1996).
69. Birck R, Warnatz K, Lorenz HM et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 14 (2), 440–447 (2003).
70. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10 (2), 79–93 (2005).
71. Daikeler T, Kotter I, Bocelli Tyndall C et al. Haematopoietic stem cell transplantation for vasculitis including Behcet’s disease and polychondritis – a retrospective analysis of patients recorded to the European Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) databases and a review of the literature. Ann. Rheum. Dis. DOI 2006.056630 (2006). (Epub ahead of print).
72. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int. 63 (3), 1079–1085 (2003).
73. Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin. Diagn. Lab. Immunol. 10 (5), 769–774 (2003).
74. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 51 (2), 269–273 (2004).
75. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43 (9), 2025–2033 (2000).
76. Carrington CB, Liebow A. Limited forms of angiitis and granulomatosis of Wegener’s type. Am. J. Med. 41 (4), 497–527 (1966).
77. McCluskey PJ, Watson PG, Lightman S et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 106 (12), 2380–2386 (1999).
78. Albini TA, Zamir E, Read RW et al. Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology 112 (10), 1814–1820 (2005).
79. Kwan AS, Rose GE. Lacrimal drainage surgery in Wegener’s granulomatosis. Br. J. Ophthalmol. 84 (3), 329–331 (2000).
80. Hardwig PW, Bartley GB, Garrity JA. Surgical management of nasolacrimal duct obstruction in patients with Wegener’s granulomatosis. Ophthalmology 99 (1), 133–139 (1992).
81. Booth AD, Almond MK, Burns A et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41 (4), 776–784 (2003).